JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Начало・Списък с акции・Atossa Genetics Inc

Atossa Genetics Inc

Затворен

0.92 1.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.92

Максимум

0.93

Ключови измерители
By Trading Economics
Приходи	-1.7M -8.4M
Служители	15
EBITDA	-1.3M -8.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+572.04% upside

Дивиденти
By Dow Jones
Следващи печалби	11.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	32M 130M
Предишно отваряне	-0.18
Предишно затваряне	0.92

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

0.7955 / 0.898 Подкрепа & съпротива

Atossa Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.10.2025 г., 18:41 ч. UTC

Печалби

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24.10.2025 г., 18:31 ч. UTC

Печалби

Correction to Procter & Gamble to Focus on Innovation

24.10.2025 г., 16:25 ч. UTC

Значими двигатели на пазара

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24.10.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24.10.2025 г., 18:52 ч. UTC

Печалби

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:41 ч. UTC

Печалби

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:03 ч. UTC

Печалби

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24.10.2025 г., 18:02 ч. UTC

Печалби

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24.10.2025 г., 18:00 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24.10.2025 г., 16:57 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24.10.2025 г., 16:54 ч. UTC

Пазарно говорене

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24.10.2025 г., 16:44 ч. UTC

Пазарно говорене

Печалби

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24.10.2025 г., 16:39 ч. UTC

Пазарно говорене

Печалби

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24.10.2025 г., 16:33 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:23 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 16:07 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Atossa Genetics Inc Прогноза

Ценова цел

By TipRanks

572.04% нагоре

12-месечна прогноза

Среден 6.25 USD 572.04%

Висок 7.75 USD

Нисък 4 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Atossa Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Atossa Genetics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.7955 / 0.898Подкрепа & съпротива

Recent bullish events outweigh bearish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.